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What’s the MO?*Nathaniel Reichek, MDyzSEE PAGES 930 AND 940S ince the early days in research on myocardialinfarction (MI), it has been recognized that MIsize, whether determined by anatomic, electro-
cardiographic, enzymatic, or imaging methods, and
post-MI adverse left ventricular (LV) remodeling are
important determinants of early and late major
myocardial adverse cardiac events (MACE). In studies
of myocardial reperfusion, both in experimental
models and in patients, the realization that reperfu-
sion injury could exacerbate the effects of MI also
came to the fore early on, and the role of microvas-
cular obstruction (MO) consequent to reperfusion
injury has been extensively recognized. The potential
role of cardiac magnetic resonance (CMR) for depic-
tion and evaluation of MI using gadolinium contrast
became apparent as early as the late 1980s in work
from Willerson’s group (1), although the potential
relevance of CMR in coronary disease was really not
appreciated until the contributions of Pohost and
colleagues (2) on quantitation of ventricular size
and function in the early 1990s. Work on the role of
MO in MI in the late ’90s contributions of Wu, Lima,
and Kim at Hopkins (3–5), followed by development
of deﬁnitive methods for quantitation of MI size and
transmural extent with CMR by Kim, Judd, and Simo-
netti (5) at Northwestern and Siemens, has made CMR
the deﬁnitive technique for infarct sizing and detec-
tion of MO in vivo. More recently, CMR has provided
means for pixel-level quantitation of myocardial
perfusion and reliable detection of myocardial edema
as a result of reversible injury in the noninfarcted
portion of the risk region, so that the risk region
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tion of intramyocardial hemorrhage (IMH) as a
component of reperfusion injury, closely related to
MO, has more recently come to the fore. However,
as is often the case, the interplay and importance of
many closely related MI variables, including infarct
size, the effectiveness and timing of reperfusion,
severity and extent of reperfusion injury, MO, IMH,
post-MI LV remodeling, and extent of coronary dis-
ease have left it unclear which are the strongest corre-
lates and potential prognostic indicators of post-MI
MACE, including cardiac death and adverse post-MI
LV remodeling, and how best they should relate to
therapeutic decision making. To complicate clinical
matters further, CMR, still the most robust method
for infarct sizing, detection of MO, and evaluation of
IMH, myocardial salvage by reperfusion, and post-
MI LV remodeling, is also the least widely available,
particularly in the United States, as well as the most
intricate and costly of cardiac imaging technologies
and has been affected greatly by turf wars between
radiologists and cardiologists. Consequently, use of
CMR for evaluation of MI has been more widely
applied in European centers, as a result in all likeli-
hood of greater centralization of costly technology
and of reperfusion therapy for MI, but its use has
been limited in the United States.This issue of iJACC contains 2 valiant efforts to
unravel the conundrum with regard to the relative
prognostic associations of various CMR ﬁndings in
MI. The answers obtained are very helpful, but many
important questions remain unanswered.
Hamirani et al. (6) at the University of Virginia
have performed a conventional meta-analysis start-
ing with some 33 studies bearing on MO and LV
remodeling and 18 addressing MO and MACE.
Because CMR methods for assessment of MO varied
widely and were evolving over the long time span
(1998 to 2014) represented by these studies, they
separately considered early post-contrast MO
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954imaging, either during ﬁrst-pass perfusion imaging or
immediately thereafter, and late MO imaging at the
time of conventional CMR delayed-enhancement
imaging for sizing infarction. Because many reports
lacked critical components of the data sought, in the
end, they evaluated results on 698 patients in 10
studies for early MO in relationship to MACE, 2,132
patients in 7 studies for late MO/MACE, and 631 pa-
tients in 9 studies for late MO/remodeling.
By contrast, van Kranenburg et al. (7), writing for a
consortium including Dutch, German, French, Span-
ish, Norwegian, Austrian, and U.S. sites, was able to
obtain, combine, and uniformly re-evaluate the
detailed individual data on 1,025 patients with
ST-segment elevation MI previously reported in 8
published studies—what might be termed a revisionist
meta-analysis. They have focused exclusively on late
MO, MACE, infarct size, and early post-MI LV size and
function.
In general, the results are quite concordant. Late
MO was found in >50% of patients in both studies,
whereas the MACE risk of MO was more than 4-fold
(hazard ratio [HR]1: 4.3 [95% conﬁdence interval (CI):
2.19 to 8.43] vs. HR2: 4.68 [95% CI: 2.86 to 7.66])
unadjusted for covariates (6,7). After multivariate
adjustment, both studies supported the independent
effect of MO on MACE, which could be most rigor-
ously and consistently deﬁned by van Kranenburg
et al. (7) (MACE adjusted HR: 3.74 [95% CI: 2.21 to
6.34]) considering age, diabetes, multivessel disease,
Thrombolysis In Myocardial Infarction ﬂow grade
post-PCI, LV ejection fraction (EF), infarct size as %LV
mass, and LV end-diastolic volume index. By
contrast, infarct size per se was less powerful and not
signiﬁcantly associated with MACE after multivariate
adjustment. In the Virginia study (6), early and late
MO were also closely associated, as expected, as were
late MO and IMH. Late MO was a much stronger
correlate of MACE than early MO but did not consis-
tently add power to infarct size for late remodeling
among individual studies evaluated.
These analyses are very useful and certainly
advance the ﬁeld, although the limitations of the
available data for each, the potential for recruitment
bias, and the evolving status of reperfusion, patient
management, and CMR over the time periods covered
are important limitations. However, the general state
of our understanding of CMR ﬁndings in MI, in rela-
tion to outcomes of MI and post-MI remodeling still
points to important questions for which we have no
answers. First, on a practical level, after more than 40
years of research on reperfusion injury and its pre-
vention in both surgical myocardial preservation
and clinical management of MI, effective, widelyaccepted approaches to the problem in MI have
not yet developed. Although remote ischemic pre-
conditioning, administration of cyclosporine, hypo-
thermia, and other emerging modalities seem
promising, much further work needs to be done.
Secondly, although it is clear that CMR offers valu-
able tools for assessment of myocardial damage and
its consequences in MI, a compelling case for routine
clinical use of CMR is lacking, absent the means to
use the results to make therapeutic choices that
improve outcomes. Unfortunately, this applies to
assessment of LV size and function, as well as tissue
composition and perfusion parameters, despite
CMR’s greater reproducibility of LV volumes and EF.
After all, the surviving binary treatment guidelines
based on EF were derived from other imaging
methods that do not consistently agree closely with
CMR in the same patient. Indeed, reports from a
number of centers have demonstrated relatively
weak correlations between CMR EF and echocardi-
ography or planar multigated acquisition EF and
sizable proportions of attribution errors for echocar-
diography or multigated acquisition assessment of
binary EF cutpoints between 30% and 40% when
CMR EF is used as a reference standard. Thus, addi-
tional large-scale trials on the basis of CMR would be
required to rigorously deﬁne the role of CMR EF in
even well-established therapeutic choices. Lastly, a
much better understanding of the mechanisms that
determine the roles of intramyocardial hemorrhage
and MO in adverse post-MI LV remodeling and the
effects of MO on MACE is badly needed and cannot be
accomplished with a continued stream of relatively
small descriptive studies, bridged by meta-analysis.
Rather, much larger-scale, closely coordinated inter-
national research efforts on MI incorporating CMR and
evaluating potential therapeutic interventions, as well
as the funding to support them, are needed. After all,
although death rates from coronary disease in devel-
oped Western nations reportedly declined to an
extraordinary degree in the late 20th century (up to
50% to 80%) with treatment advances accounting
for anywhere from one-quarter to one-half of the re-
ductions in various reports, declines have reportedly
slowed, coronary disease remains the leading cause of
death throughout the world, and its rapidly expanding
impact in large populations in low- and middle-
income countries hardly augurs well for the future.
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